Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › Efocipegtrutide

Efocipegtrutide

GIP/GLP-1/GCG · s.c. · Hanmi

Data cut 12 November 2026 · page built 16 November 2026 · 0 trial arms · 0 trials with results · 1 registered trials · see on the pipeline board

Summary

Also known as
HM15211, Hanmi
Mechanism
GIP/GLP-1/GCG
Route
s.c.
Company
Hanmi
Highest development stage
phase 2
Status (as of data cut)
Phase 2 in biopsy-confirmed MASH verify
Next milestone
Phase 2 results

Sources for the status

Indications: regulatory and evidence status

IndicationCodeStatusEvidence
Obesity0 no data
T2D0 no data
CV outcomes0 no data
CKD0 no data
HFpEF0 no data
MASH1 phase 2 / signalPhase 2 in biopsy-confirmed MASHHM15211 phase 2
Sleep apnoea0 no data
Knee OA0 no data
Alzheimer's0 no data

4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.

Trial arms: weight, HbA1c and tolerability

No trial arms with extracted efficacy or tolerability data yet.

Registered trials (1)

From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
HM-TRIA-201
Efocipegtrutide (HM15211) in Adults With Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)
MASHPhase 2completed2020-07 → 2026-06215Completed; results not in the atlas yetNCT04505436

Primary sources

No source recorded.

How to cite this page

Medical Adviser's Group. Incretin Atlas: Efocipegtrutide. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/efocipegtrutide/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.